US2020054695A1PendingUtilityA1

Active substance of lactobacillus plantarum gkm3, a composition comprising thereof and its use for promoting longevity

Assignee: GRAPE KING BIO LTDPriority: Aug 16, 2018Filed: Aug 15, 2019Published: Feb 20, 2020
Est. expiryAug 16, 2038(~12.1 yrs left)· nominal 20-yr term from priority
A61P 21/00A61K 35/747A23L 33/135A23K 10/18A23C 9/152A23V 2002/00A23L 2/52A61P 25/28A61P 39/00A61P 39/06A61K 9/0095A61P 25/00A61K 2035/115A61K 9/19C12R 1/25C12R 2001/25C12N 1/205A23V 2400/169
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides an active substance of Lactic Acid Bacteria, a composition comprising thereof and its use for promoting longevity, especially for increasing Cisd2 gene expression, reducing mitochondrial damage and delaying aging conditions such as nerve degeneration and sarcopenia.

Claims

exact text as granted — not AI-modified
1 . A longevity-promoting composition comprising a  Lactobacillus plantarum , wherein the  Lactobacillus plantarum  is deposited (No. 14565) at China General Microbiological Culture Collection Center. 
     
     
         2 . A longevity-promoting composition comprising an active substance of  Lactobacillus plantarum  of an effective amount, wherein the  Lactobacillus plantarum  is deposited (No. 14565) at China General Microbiological Culture Collection Center. 
     
     
         3 . The composition of  claim 2 , wherein the active substance is prepared by the following method:
 (a) streaking lactic acid bacteria on a solid-state media to produce single colonies; and   (b) inoculating a single colony of lactic acid bacteria cultured at step (a) to a liquid culture for liquid-state culture.   
     
     
         4 . The composition of  claim 3 , wherein said method further comprises the following steps:
 (c) centrifuging the liquid culture cultured at step (b) to obtain a bacterial pellet; and   (d) freeze-drying the bacterial pellet obtained at step (c).   
     
     
         5 . The composition of  claim 3 , wherein step (b) is carried out at 30 to 50° C., in nitrogen or carbon dioxide of 0 to 1 VVM, rotate at 10 to 100 rpm, and/or incubate for 16 to 24 hours. 
     
     
         6 . The composition of  claim 4 , wherein the temperature for the freeze-drying at step (d) is −196 to −40° C. 
     
     
         7 . The composition of  claim 1 , the composition comprising an additive selected from the group consisting of an excipient, preservative, diluent, filler, absorption enhancer, sweetener and a combination thereof. 
     
     
         8 . The composition of  claim 2 , the composition comprising an additive selected from the group consisting of: an excipient, preservative, diluent, filler, absorption enhancer, sweetener and a combination thereof. 
     
     
         9 . The composition of  claim 1 , the composition being a drug, feed, drink, nutritional supplement, dairy product or health food. 
     
     
         10 . The composition of  claim 2 , the composition being a drug, feed, drink, nutritional supplement, dairy product or health food. 
     
     
         11 . The composition of  claim 1 , the composition taking the form of a powder, tablet, granule, suppository, microcapsule, ampoule/ampule, liquid spray or suppository form. 
     
     
         12 . The composition of  claim 2 , the composition taking the form of a powder, tablet, granule, suppository, microcapsule, ampoule/ampule, liquid spray or suppository form. 
     
     
         13 . A method for manufacturing a composition of  claim 1  for promoting longevity. 
     
     
         14 . The method of  claim 13 , wherein for promoting longevity, a subject having been administered the active substance exhibits increased Cisd2 gene expression compared to a subject that has not been administered the active substance. 
     
     
         15 . The method of  claim 13 , wherein for promoting longevity, a subject having been administered the active substance exhibits reduced and delayed mitochondrial damage compared to a subject that has not been administered the active substance. 
     
     
         16 . The method of  claim 13 , wherein for promoting longevity, a subject having been administered the active substance exhibits delayed aging conditions of nerve degeneration, sarcopenia or a combination thereof, compared to a subject that has not been administered the active substance. 
     
     
         17 . A method for manufacturing a composition of  claim 2  for promoting longevity.

Join the waitlist — get patent alerts

Track US2020054695A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.